Business Context and Reporting Period
Company: NanoViricides, Inc. (NNVC)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2011
Business Stage: Development Stage Company
Operations: NanoViricides is a nano-biopharmaceutical company focused on discovering and developing therapeutics for life-threatening viral infections (including HIV, Hepatitis, Influenza, and Ebola). The company holds exclusive perpetual licenses from TheraCour Pharma, Inc. for its core technology. As of the reporting date, the company has generated no revenue and has not commenced commercial product sales.
Key Financial Metrics
| Metric | Three Months Ended Mar 31, 2011 |
Nine Months Ended Mar 31, 2011 |
Balance Sheet Mar 31, 2011 |
|---|---|---|---|
| Revenues | $0 | $0 | N/A |
| Net Loss | $(2,546,687) | $(5,219,544) | N/A |
| Accumulated Deficit | N/A | N/A | $(21,959,287) |
| Cash and Cash Equivalents | N/A | N/A | $7,763,391 |
| Total Assets | N/A | N/A | $9,858,491 |
| Total Current Liabilities | N/A | N/A | $809,709 |
| Operating Expenses (9mo) | N/A | $5,167,916 | N/A |
| Net Cash Used in Operating Activities (9mo) | N/A | $(3,666,578) | N/A |
Liquidity: The company reported a cash balance of $7.76 million as of March 31, 2011. Management estimates this is sufficient to fund operations through December 31, 2012, at current expenditure rates.
Material Changes vs. Prior Period
- Net Loss Increase: Net loss for the nine months ended March 31, 2011, was $5.22 million, compared to $4.08 million for the same period in 2010. This increase is primarily driven by higher Research and Development (R&D) expenses ($3.52 million vs. $2.68 million) and General and Administrative (G&A) expenses ($1.60 million vs. $1.36 million).
- Derivative Liability Elimination: The balance sheet shows a derivative liability of $0 as of March 31, 2011, compared to $1.04 million as of June 30, 2010. This reduction resulted from the conversion of Series B Convertible Preferred Stock into common stock and fair value adjustments.
- Related Party Payables: Accounts payable to related parties decreased significantly from $1.19 million (June 30, 2010) to $463,308 (March 31, 2011), reflecting payments made during the period.
- Financing Activity: The company raised $4.65 million in net cash from financing activities during the nine-month period, primarily through the issuance of Series B Convertible Preferred Stock.
Guidance, Outlook, and Risks
Capital Requirements: Management estimates a need for an additional $10 million to $15 million over the next 18 months to fund toxicology studies, efficacy studies, and the preparation of an Investigational New Drug (IND) application for the FDA. Specific budgeted expenses include $5 million for R&D, $1.25 million for corporate overhead, and $3.5 million for capital and staffing costs.
Recent Financing (Subsequent Event): On April 18, 2011, the company entered into an agreement to sell up to 500,000 shares of Series B Convertible Preferred Stock. An initial closing on April 19, 2011, raised $2.5 million. A subsequent closing for an additional $2.5 million is contingent on meeting specific conditions.
Development Progress:
- Influenza: Optimized FluCide candidates demonstrated superior efficacy compared to Tamiflu in lethal animal models, showing 1,000-fold reduction in viral load and extended survival.
- Herpes: Cell culture studies showed significant inhibition of HSV-1 infectivity.
- Other Programs: Ongoing studies for Dengue, Ebola/Marburg, Rabies, and HIV.
Risks and Contingencies:
- Going Concern: While currently funded through late 2012, the company has a history of losses and no revenue. Future profitability is not assured.
- Regulatory Risk: No drug candidates have completed safety profile studies required for an IND submission. Success in pre-clinical studies does not guarantee clinical success.
- Related Party Dependence: The company relies on TheraCour Pharma, Inc. (controlled by the company's President) for technology licensing and manufacturing. TheraCour owns approximately 24.9% of the company's common stock.
Investor Verification Checklist
- Cash Runway: Verify the accuracy of the $7.76 million cash balance and the projected burn rate to confirm the ability to operate through December 2012.
- Financing Terms: Review the terms of the Series B Convertible Preferred Stock, specifically the automatic conversion mechanics, dividend accruals, and potential dilution to common shareholders.
- Related Party Transactions: Scrutinize the ongoing financial relationship with TheraCour Pharma, Inc., including development fees ($876,860 for the nine months ended March 31, 2011) and the security advance held by TheraCour ($313,656).
- Derivative Accounting: Confirm the valuation methodology used for the elimination of the derivative liability and ensure no residual contingent liabilities exist.
- Pre-Clinical Data: Assess the validity and reproducibility of the reported animal study results (Influenza and Herpes) as these are preliminary and not yet confirmed by FDA-regulated toxicology studies.